CA3207282A1 - Abiraterone prodrugs - Google Patents

Abiraterone prodrugs Download PDF

Info

Publication number
CA3207282A1
CA3207282A1 CA3207282A CA3207282A CA3207282A1 CA 3207282 A1 CA3207282 A1 CA 3207282A1 CA 3207282 A CA3207282 A CA 3207282A CA 3207282 A CA3207282 A CA 3207282A CA 3207282 A1 CA3207282 A1 CA 3207282A1
Authority
CA
Canada
Prior art keywords
abiraterone
subject
decanoate
pharmaceutical composition
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3207282A
Other languages
English (en)
French (fr)
Inventor
Matthew J. Sharp
William R. Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Propella Therapeutics Inc
Original Assignee
Propella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propella Therapeutics Inc filed Critical Propella Therapeutics Inc
Publication of CA3207282A1 publication Critical patent/CA3207282A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3207282A 2021-02-15 2022-02-14 Abiraterone prodrugs Pending CA3207282A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149550P 2021-02-15 2021-02-15
US63/149,550 2021-02-15
PCT/US2022/016278 WO2022174134A1 (en) 2021-02-15 2022-02-14 Abiraterone prodrugs

Publications (1)

Publication Number Publication Date
CA3207282A1 true CA3207282A1 (en) 2022-08-18

Family

ID=80625499

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3207282A Pending CA3207282A1 (en) 2021-02-15 2022-02-14 Abiraterone prodrugs

Country Status (6)

Country Link
US (3) US11957696B2 (enExample)
EP (1) EP4291159A1 (enExample)
JP (1) JP2024506382A (enExample)
CN (1) CN117120034A (enExample)
CA (1) CA3207282A1 (enExample)
WO (1) WO2022174134A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
EP4077309A1 (en) 2019-12-19 2022-10-26 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP7850366B2 (ja) * 2020-09-02 2026-04-23 アステラス ユーエス エルエルシー アビラテロンプロドラッグ
CA3207282A1 (en) * 2021-02-15 2022-08-18 Matthew J. Sharp Abiraterone prodrugs
CN118215466A (zh) * 2021-09-08 2024-06-18 普洛佩拉治疗公司 口服阿比特龙制剂
KR20240167653A (ko) 2022-03-01 2024-11-27 프로펠라 쎄라퓨틱스, 인크. 아비라테론 데카노에이트 프로드러그 및 요법에서의 용도
US20240180900A1 (en) * 2022-10-24 2024-06-06 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2024107928A1 (en) 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy
CN116046950A (zh) * 2023-01-18 2023-05-02 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) 一种检测醋酸阿比特龙中5种杂质的方法
WO2024186523A2 (en) * 2023-03-07 2024-09-12 Board Of Regents, The University Of Texas System Glucocorticoid receptor antagonists for cancer treatment

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
DE60045751D1 (de) * 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2506855A4 (en) 2009-11-30 2014-07-30 Harbor Biosciences Inc ANTICARCINOMA COMPOUNDS AND SCREENING METHODS
CA2819515A1 (en) 2010-12-16 2012-06-21 Biomarin Pharmaceutical Inc. Cyp11b, cyp17, and/or cyp21 inhibitors
JP6091510B2 (ja) 2011-10-10 2017-03-08 ザック システム １７−置換ステロイドの製造方法
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
CA2871314A1 (en) 2012-04-23 2013-10-31 Alphora Research Inc. Process for preparation of 17-substituted steroids
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
US20140011992A1 (en) 2012-12-20 2014-01-09 Crystal Pharma, S.A.U. Synthesis of abiraterone and related compounds
DK2945628T3 (da) * 2013-01-15 2020-05-04 Aragon Pharmaceuticals Inc Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
US20150337003A1 (en) 2013-01-18 2015-11-26 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
EP2969227B1 (en) 2013-03-15 2019-05-08 Iceutica Inc. Abiraterone acetate formulation
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
EP3035938B1 (en) 2013-09-10 2020-08-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
CN106456795A (zh) 2014-03-03 2017-02-22 辛塔医药品有限公司 靶向治疗学
EP3131586A4 (en) 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
CN104017045B (zh) 2014-06-23 2016-01-13 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
BR112017003219A2 (pt) 2014-09-18 2017-11-28 Iceutica Inc formulação de acetato de abiraterona e métodos de uso
CN104356191A (zh) 2014-09-29 2015-02-18 上海延安药业（湖北）有限公司 阿比特龙单琥珀酸酯及其制备方法
WO2016082792A1 (zh) 2014-11-28 2016-06-02 四川海思科制药有限公司 一种阿比特龙衍生物及其制备方法和医药用途
CN104710499A (zh) 2015-02-15 2015-06-17 重庆医药工业研究院有限责任公司 一种丙酸阿比特龙的晶型及其制备方法
CA3008909C (en) 2015-12-23 2023-10-03 The University Of British Columbia Lipid-linked prodrugs
JP6842474B2 (ja) 2016-02-02 2021-03-17 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． ステロイド系化合物、当該化合物を含む組成物及びその使用
CN109922809B (zh) 2016-10-11 2021-08-13 珠海贝海生物技术有限公司 阿比特龙衍生物及其制剂
CN106977577A (zh) 2017-04-21 2017-07-25 湖南师范大学 两类阿比特龙衍生物的合成
US20190105332A1 (en) * 2017-10-11 2019-04-11 Janssen Oncology, Inc. Methods of treating prostate cancer
CN118684633A (zh) 2018-10-18 2024-09-24 埃萨制药股份有限公司 雄激素受体调节剂及其使用方法
CN113473974A (zh) 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 药物组合物
JP7644713B2 (ja) * 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
EP3941478A4 (en) * 2019-03-18 2022-12-28 Dispersol Technologies, LLC PHARMACEUTICAL FORMULATIONS OF ABIRATERON CYCLIC OLIGOMERS AND METHODS OF PREPARATION AND ADMINISTRATION THEREOF
JP7850366B2 (ja) * 2020-09-02 2026-04-23 アステラス ユーエス エルエルシー アビラテロンプロドラッグ
CN113929727A (zh) 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
CA3207282A1 (en) 2021-02-15 2022-08-18 Matthew J. Sharp Abiraterone prodrugs
CN118215466A (zh) 2021-09-08 2024-06-18 普洛佩拉治疗公司 口服阿比特龙制剂

Also Published As

Publication number Publication date
JP2024506382A (ja) 2024-02-13
CN117120034A (zh) 2023-11-24
WO2022174134A1 (en) 2022-08-18
US20220265681A1 (en) 2022-08-25
EP4291159A1 (en) 2023-12-20
US20260014172A1 (en) 2026-01-15
US20240139212A1 (en) 2024-05-02
US11957696B2 (en) 2024-04-16

Similar Documents

Publication Publication Date Title
US11957696B2 (en) Abiraterone prodrugs
US12138273B2 (en) Abiraterone prodrugs
US20250025417A1 (en) Oral abiraterone formulations
JP7850366B2 (ja) アビラテロンプロドラッグ
US20250186463A1 (en) Abiraterone decanoate prodrugs and use in therapy
WO2024107928A1 (en) Abiraterone decanoate composition and use in therapy
HK40096901A (zh) 阿比特龙前药
HK40096900A (zh) 阿比特龙前药
HK40103488A (en) Abiraterone prodrugs
HK40120426A (zh) 阿比特龙前药
HK40130201A (zh) 阿比特龙前药
HK40129794A (zh) 阿比特龙前药
HK40065545B (zh) 阿比特龙前药

Legal Events

Date Code Title Description
R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241119

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250317